India's new policy to protect research participants | Johns Hopkins University Baltimore-India Clinical Trials Unit

India’s new policy to protect research participants

Citation: Sugarman J, Bhan A, Bollinger R, Gupta A. India’s new policy to protect research participants. BMJ. 2013 Jul 31;347:f4841. doi: 10.1136/bmj.f4841. PMID: 23903456.

Access full article:

http://www.ncbi.nlm.nih.gov/pubmed/23903456

BMJ. 2013 Jul 31;347:f4841. doi: 10.1136/bmj.f4841. PubMed PMID: 23903456

CRS

Topics

A5342: Evaluating the Safety, Tolerability, and Effect of a...

The purpose of this study is to evaluate the safety, tolerability, and effect of an experimental human monoclonal antibody...

A5128: Consent for Use of Stored Patient Specimens for...

The purpose of this study is to obtain informed consent to use stored human biological materials (HBM) (e.g., blood and other...

A5332: Randomized Trial to Prevent Vascular Events in HIV...

REPRIEVE (A5332) is a large double-blind, randomized, placebo-controlled study of pitavastatin or placebo for about 72 months....

P1070, Dose-Finding and Pharmacogenetic Study of Efavirenz...

Efavirenz (EFV) is an anti-HIV medicine that is commonly used to treat HIV infection in adults and children older than 3 years...

A5314: Effect of LDMTX on Inflammation in HIV-infected...

A5314 is a phase II randomized, double-blind, placebo-controlled 36-week trial that will examine the safety and efficacy of...

Johns Hopkins University Baltimore-India Clinical Trials Unit